Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Share News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.00
Ask: 40.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.263%)
Open: 39.00
High: 39.00
Low: 39.00
Prev. Close: 39.00
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

Tue, 30th Apr 2024 19:54

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Issues business update for the first quarter. Reports first quarter revenue of USD4.0 million from around 28,800 prescriptions of Accrufer. Prescriptions rose 1% from the fourth quarter and 174% from a year prior. Further, strengthens balance sheet through an accounts receivable financing with Sallyport Commercial Finance and amends its existing USD20 million debt facility agreement with SWK Funding LLC, with more favourable loan covenant terms. Shield also expects to turn cashflow positive in the second half of 2025 with its current resources. Chief Executive Greg Madison says: "We observed several encouraging growth signals during Q1 2024 including rising prescriptions in key states such as California and New York, after receiving access to Medicaid in those populous states." Confirms full-year guidance.

----------

Software Circle PLC - Manchester-based software business acquirer - Issues pre-close trading statement for year ending March. Says revenue rises to GBP16.1 million from GBP11.7 million. Adjusted earnings before interest, tax, amortisation and depreciation increases to GBP1.7 million from GBP400,000. "It has been another year of progress and growth despite some unpleasant headwinds from our discontinued operations that are now firmly in our rear-view mirror," company says. Expresses cautious optimism for the coming year. Intends to release full-year results in July.

----------

ACG Acquisition Co Ltd - Special purpose acquisition company looking to benefit from favourable price conditions for new economy metals and other mining materials - Releases results for 18 months to December 31. Comparative figures are for period June 22, 2021, to June 30, 2022. Administrative costs are GBP20.9 million compared to GBP2.7 million. Pretax loss is GBP25.9 million compared with GBP2.7 million. No dividend paid, unchanged.

----------

Gem Diamonds Ltd - diamond miner which has operations in Lesotho and Botswana - Announces the recovery of a 118.74 carat type II white diamond recovered at the Letseng mine in Lesotho, the fifth greater than 100 carat diamond recovered to date this year.

----------

Light Science Technologies Holdings PLC - Derbyshire, England-based agricultural lighting and monitoring systems provider - Provides business update for the year to November 30. In Contract Electronics Manufacturing says current forward order book remains strong at over GBP4 million, putting it on track when combined with orders already invoiced, to meet internal sales expectations for the first half of 2024, and setting a solid foundation for the second half of the year. Adds the pipeline of quoted business currently stands at nearly GBP40 million in the Controlled Environment Agriculture division. The Passive Fire Protection unit has a strong pipeline of quoted work, now valued over GBP9 million.

----------

Vox Valor Capital Ltd - London-based technology investment company - Says 2023 pretax loss narrows to USD569,585 from USD3.2 million in 2022. Revenue falls to USD5.6 million from USD13.8 million due to the disposal of the Russian subsidiary of the group. Chair John Booth says: "For the year ahead, we look forward to seeing Vox Valor grow further both organically and through mergers and acquisitions. The company is continuing to identify potential acquisitions that are complimentary to the group's strategy where it can generate meaningful synergies from its mobile marketing expertise and technology. The organic growth plans of the group include the expansion of the group's mobile marketing services and technology offer (Mobio) in the UK, Europe and the US."

----------

Beximco Pharmaceuticals Ltd - generic pharmaceutical products and active ingredients' manufacturer - Says revenue in the three months to March 31, the financial third quarter, rises to GBP79.5 million from GBP74.6 million. Post-tax profit increases to GBP9.9 million from GBP7.1 million. Managing Director Iqbal Ahmed comments: "I am pleased to report strong double-digit growth for the period, despite the impact of macroeconomic headwinds, including challenging exchange rates and elevated domestic inflation. While we expect these headwinds to remain for the foreseeable future, the year-on-year improvement in profitability demonstrates the resilience and strength of our business as we continue to provide high-quality, affordable medicines to patients in Bangladesh and around the globe. We will stay focused on executing on our growth strategy for the remainder of the year and look forward to providing a further update at our full-year results."

----------

Cordiant Digital Infrastructure Ltd - investor in data centres, telecommunications towers, and fibre networks in the UK, Europe and North America - Chair & Co-Founder Steven Marshall in April buys 310,326 ordinary shares at an average price of 64.0 pence each. Worth around GBP198,000. Marshall now holds around 8.2 million shares in Cordiant, around 1.4% of the entire issued share capital of the company.

----------

Fusion Antibodies PLC - Belfast-based contract researcher, which provides discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Issues trading update for the year ended March 31. Reports full-year of unaudited revenue of GBP1.1 million, down from GBP2.9 million the year prior. Highlights increased activity in the second half of the year. Notes "significant" increase in sales pipeline opportunities during the second half, with an order book at March 31 of GBP0.75 million, around 65% of total full-year unaudited revenue.

----------

Cloudified Holdings Ltd - AIM-listed cash shell - Releases half-year results to September 30, 2023. Reports no revenue, unchanged from a year prior, while pretax loss widens modestly to GBP554,518 from GBP539,709. This reflects higher administrative costs of GBP558,818, up from GBP540,450. Says the company actively pursues the acquisition of another company or business, in exchange for the issue of ordinary shares in a single transaction, as a "reverse takeover." Cash balance at March 31 is GBP530,000.

----------

Image Scan Holdings PLC - Loughborough, England-based x-ray screen system supplier - In the six months to March 31 says revenue falls to GBP1.1 million from GBP1.5 million. Pretax loss widens to GBP119,000 from GBP16,000, period-end order book falls to GBP729,000 from GBP1.1 million. Chief Executive Officer Vince Deery says: "The H1 2024 performance is a reduction over the same period last year, however, the pipeline is buoyed by the introduction of the new products and the participation in a large volume mainly government opportunities. The increase in margin reflects the product mix and great efforts on combatting inflationary pressures. Taking into consideration our careful cost management and the opportunity pipeline, the Board is confident of delivering a full year performance in line with market expectations."

----------

Tan Delta Systems PLC - Sheffield, England-based provider of oil-quality monitoring and maintenance systems for commercial and industrial equipment - In 2023, says revenue falls to GBP1.5 million from GBP1.6 million. Swings to pretax loss of GBP1.1 million from profit of GBP278,428 as administrative expenses balloon to GBP2.0 million from GBP686,484. Chair Simon Tucker says: "Whilst revenues were lower than prior year, I am pleased with operational progress achieved following our successful IPO in August 2023, both during the rest of 2023 but also continuing into the current year." Tucker highlights a "lean" overhead structure and material progress growing a new sales prospects pipeline to around GBP4.0 million, which he expects to start converting into sales during the second half of the current year. Additionally, Tucker notes several "very substantial" strategic customers where ongoing trials are expected to finalise in 2024 and result in long term supply contracts and commencement of revenues. "Our proposition is gaining traction and we are increasingly confident about our future prospects," Tucker adds.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Jul 2018 12:53

Monday broker round-up

(Sharecast News) - Hargreaves Lansdown: Jefferies downgrades to underperform with a target price of 1,650p.

Read more
27 Jan 2017 10:45

Beximco profits rise as it begins US exports

(ShareCast News) - Bangladeshi generic pharmaceutical products and active pharmaceutical ingredients manufacturer Beximco Pharmaceuticals announced its unaudited financial results for the six months to 31 December on Friday. The AIM-traded company said net sales increased by 13.6% to BDT 7,630.6m or

Read more
25 Jan 2017 16:10

Beximco Pharma partners with BioCare in Malaysia

(ShareCast News) - Generic pharmaceutical products manufacturer Beximco Pharmaceuticals announced the creation of a joint venture with BioCare Manufacturing, based in Malaysia, as the company's first overseas manufacturing collaboration on Wednesday. The AIM-traded firm said that under the terms of

Read more
21 Nov 2016 10:49

Beximco Pharmaceuticals Highlights Continued Progress

Read more
25 Oct 2016 07:07

Beximco Gets US Approval For Generic Cardiovascular Drug Sotalol

Read more
20 Oct 2016 11:01

Beximco sales grow in first half

(ShareCast News) - Generic pharmaceutical products and active ingredients manufacturer Beximco Pharmaceuticals posted audited results for the half year to 30 June on Thursday, with net sales growing by 13.1% to BDT 7.07bn. The AIM-traded firm's export sales grew by 5.3%, and domestic market sales in

Read more
5 Aug 2016 07:21

Beximco Commences Export Of Carvedilol Hypertension Drug To US

Read more
17 Jun 2016 15:21

Beximco makes historic drug shipment to Kuwait

(ShareCast News) - Generic pharmaceutical manufacturer Beximco announced on Friday that it has commenced the export of pharmaceuticals to Kuwait. The AIM-traded firm said it marks the first time a Bangladeshi pharmaceutical company has launched products in any Gulf member country under the Gulf Coop

Read more
17 Jun 2016 07:21

Beximco Starts Export Of Pharmaceutical Products To Kuwait

Read more
9 May 2016 07:52

Beximco Pharmaceuticals Profit Grows As It Expands Geographically

Read more
6 May 2016 08:02

Beximco Postpones Annual Meeting After Change Of Financial Year

Read more
19 Nov 2015 09:02

Beximco Pharmaceuticals Gets US Approval For Carvedilol Manufacturing

Read more
24 Jul 2015 08:32

Beximco Confident In Meeting Targets As First-Half Profit Rises

Read more
24 Jun 2015 06:53

Beximco Pharmaceuticals Gets Approval From US Authorities

Read more
15 Jun 2015 08:07

Beximco Pharmaceuticals Feels Political Turmoil But Sees Recovery

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.